Salgüero FI; Hospital GM, Baniandrés RO, Ruiz GD, Roustan GG

Language: Spanish
References: 6
Page: 115-118
PDF size: 193.32 Kb.

ABSTRACT

Psoriasis is a chronic disease. Severe to moderate forms of psoriasis are associated with an increased risk of 25% of cardiovascular disease. We propose a multicenter, retrospective, observational study performed in routine practice with 61 patients with moderate-severe psoriasis in Secukinumab treatment of three hospitals in Madrid.

REFERENCES

1. Bonanad C, González-Parra E, Rivera R, Carrascosa JM, Dauden E, Olveira A et al. Clinical, diagnostic, and therapeutic implications in psoriasis associated with cardiovascular disease. Actas Dermosifiliogr. 2017; 108: 800-808.

2. Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018; 79: 345-352.

3. Van de Kerkhof PMC et al. Secukinumab’s pooled and long-term safety: analysis of 19 psoriasis clinical trials up to 5 years of treatment. SKIN The Journal of Cutaneous Medicine. 2018; 2: S18.

4. Armstrong AW, Papp K, Kircik L. Secukinumab: review of clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016; 9: S7-S12.

5. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018; 32: 1507-1514.

6. González-Cantero A. El Systematic Coronary Risk Evaluation (SCORE) infraestima el riesgo cardiovascular en pacientes con psoriasis. Estudio comparativo con la ecografía carotídea y femoral para detectar placas de ateroma. In: 46 Congreso Nacional de Dermatología y Venereología. Palma de Mallorca, Spain. May 12 /2018. Resultados no publicados.